Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

373 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Mevalonate pathway blockage enhances the efficacy of mTOR inhibitors with the activation of retinoblastoma protein in renal cell carcinoma.
Hagiwara N, Watanabe M, Iizuka-Ohashi M, Yokota I, Toriyama S, Sukeno M, Tomosugi M, Sowa Y, Hongo F, Mikami K, Soh J, Fujito A, Miyashita H, Morioka Y, Miki T, Ukimura O, Sakai T. Hagiwara N, et al. Among authors: yokota i. Cancer Lett. 2018 Sep 1;431:182-189. doi: 10.1016/j.canlet.2018.05.025. Epub 2018 May 17. Cancer Lett. 2018. PMID: 29778569
Chromosomal abnormality variation detected by G-banding is associated with prognosis of diffuse large B-cell lymphoma treated by R-CHOP-based therapy.
Mizuno Y, Tsukamoto T, Kawata E, Uoshima N, Uchiyama H, Yokota I, Maegawa S, Takimoto T, Tanba K, Matsumura-Kimoto Y, Kuwahara-Ota S, Fujibayashi Y, Yamamoto-Sugitani M, Chinen Y, Shimura Y, Horiike S, Taniwaki M, Kobayashi T, Kuroda J. Mizuno Y, et al. Among authors: yokota i. Cancer Med. 2018 Mar;7(3):655-664. doi: 10.1002/cam4.1342. Epub 2018 Feb 23. Cancer Med. 2018. PMID: 29473332 Free PMC article.
Novel prediction model of renal function after nephrectomy from automated renal volumetry with preoperative multidetector computed tomography (MDCT).
Isotani S, Shimoyama H, Yokota I, Noma Y, Kitamura K, China T, Saito K, Hisasue S, Ide H, Muto S, Yamaguchi R, Ukimura O, Gill IS, Horie S. Isotani S, et al. Among authors: yokota i. Clin Exp Nephrol. 2015 Oct;19(5):974-81. doi: 10.1007/s10157-015-1082-6. Epub 2015 Jan 25. Clin Exp Nephrol. 2015. PMID: 25618493
Multicenter, randomized, open-label Phase II study comparing S-1 alternate-day oral therapy with the standard daily regimen as a first-line treatment in patients with unresectable advanced pancreatic cancer.
Yamaue H, Shimizu A, Hagiwara Y, Sho M, Yanagimoto H, Nakamori S, Ueno H, Ishii H, Kitano M, Sugimori K, Maguchi H, Ohkawa S, Imaoka H, Hashimoto D, Ueda K, Nebiki H, Nagakawa T, Isayama H, Yokota I, Ohashi Y, Shirasaka T. Yamaue H, et al. Among authors: yokota i. Cancer Chemother Pharmacol. 2017 Apr;79(4):813-823. doi: 10.1007/s00280-017-3250-8. Epub 2017 Mar 1. Cancer Chemother Pharmacol. 2017. PMID: 28251282 Clinical Trial.
The Kyoto Prognostic Index for patients with diffuse large B-cell lymphoma in the rituximab era.
Kobayashi T, Kuroda J, Yokota I, Tanba K, Fujino T, Kuwahara S, Isa R, Yamaguchi J, Kawata E, Akaogi T, Uchiyama H, Kaneko H, Uoshima N, Kobayashi Y, Teramukai S, Taniwaki M. Kobayashi T, et al. Among authors: yokota i. Blood Cancer J. 2016 Jan 15;6(1):e383. doi: 10.1038/bcj.2015.111. Blood Cancer J. 2016. PMID: 26771809 Free PMC article. No abstract available.
Pomalidomide with or without dexamethasone for relapsed/refractory multiple myeloma in Japan: a retrospective analysis by the Kansai Myeloma Forum.
Matsumura-Kimoto Y, Kuroda J, Kaneko H, Kamitsuji Y, Fuchida SI, Nakaya A, Shibayama H, Uoshima N, Yokota I, Uchiyama H, Yagi H, Kosugi S, Matsui T, Ishikawa J, Matsuda M, Ohta K, Iida M, Tanaka H, Kobayashi M, Wada K, Shimazaki C, Nomura S, Imada K, Hino M, Matsumura I, Kanakura Y, Takaori-Kondo A; Kansai Myeloma Forum Investigators. Matsumura-Kimoto Y, et al. Among authors: yokota i. Int J Hematol. 2018 May;107(5):541-550. doi: 10.1007/s12185-018-2416-4. Epub 2018 Jan 29. Int J Hematol. 2018. PMID: 29380179
A randomized phase II study evaluating pyridoxine for the prevention of hand-foot syndrome associated with capecitabine therapy for advanced or metastatic breast cancer.
Toyama T, Yoshimura A, Hayashi T, Kobayashi N, Saito K, Tsuneizumi M, Sawaki M, Hattori M, Nakada T, Yokota I, Iwata H. Toyama T, et al. Among authors: yokota i. Breast Cancer. 2018 Nov;25(6):729-735. doi: 10.1007/s12282-018-0879-z. Epub 2018 Jun 8. Breast Cancer. 2018. PMID: 29948956 Clinical Trial.
373 results